Mana Capital Acquisition (MAAQ) Competitors $4.07 +0.01 (+0.25%) As of 09/26/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. LFVN, KALA, PYXS, ONCY, ACOG, CGEN, HURA, EXOZ, BMEA, and IKTShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Lifevantage (LFVN), KALA BIO (KALA), Pyxis Oncology (PYXS), Oncolytics Biotech (ONCY), Alpha Cognition (ACOG), Compugen (CGEN), TuHURA Biosciences (HURA), eXoZymes (EXOZ), Biomea Fusion (BMEA), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Lifevantage KALA BIO Pyxis Oncology Oncolytics Biotech Alpha Cognition Compugen TuHURA Biosciences eXoZymes Biomea Fusion Inhibikase Therapeutics Mana Capital Acquisition (NASDAQ:MAAQ) and Lifevantage (NASDAQ:LFVN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Do institutionals & insiders hold more shares of MAAQ or LFVN? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, MAAQ or LFVN? Lifevantage has higher revenue and earnings than Mana Capital Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/ALifevantage$228.53M0.54$9.81M$0.7413.19 Is MAAQ or LFVN more profitable? Lifevantage has a net margin of 4.29% compared to Mana Capital Acquisition's net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Mana Capital Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Lifevantage 4.29%33.75%15.26% Do analysts rate MAAQ or LFVN? Lifevantage has a consensus target price of $30.50, suggesting a potential upside of 212.50%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts clearly believe Lifevantage is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MAAQ or LFVN? In the previous week, Lifevantage had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Mana Capital Acquisition. Lifevantage's average media sentiment score of 0.95 beat Mana Capital Acquisition's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Lifevantage Positive SummaryLifevantage beats Mana Capital Acquisition on 10 of the 11 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$33.07M$33.07M$2.52B$10.38BDividend YieldN/AN/A2.51%4.70%P/E RatioN/AN/A26.6526.39Price / SalesN/AN/A249.15228.43Price / CashN/AN/A47.3130.68Price / BookN/AN/A36.316.40Net IncomeN/AN/A$12.55M$276.69M7 Day Performance2.01%2.01%-0.51%-0.28%1 Month Performance7.39%7.39%3.11%6.69%1 Year Performance1,756.75%1,756.75%71.95%27.61% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$4.07+0.2%N/A+1,756.8%$33.07MN/A0.001LFVNLifevantage3.9688 of 5 stars$10.19+2.0%$30.50+199.3%-21.5%$129.32M$228.53M13.77260KALAKALA BIO4.0695 of 5 stars$19.05+4.6%$27.50+44.4%+256.1%$127.92M$3.89M-2.8130Trending NewsAnalyst DowngradeGap DownTrading HaltedPYXSPyxis Oncology2.3737 of 5 stars$2.14+3.9%$7.75+262.1%-40.9%$127.76M$2.82M-1.3460Positive NewsONCYOncolytics Biotech2.2993 of 5 stars$1.29+3.2%$5.00+287.6%+44.6%$125.45MN/A-4.7830ACOGAlpha Cognition2.7117 of 5 stars$7.08-8.3%$20.00+182.5%N/A$124.76MN/A-4.43N/APositive NewsGap DownCGENCompugen1.5446 of 5 stars$1.38flat$4.00+189.9%-23.5%$123.15M$27.86M-6.2770Positive NewsHURATuHURA Biosciences1.5961 of 5 stars$2.46+0.4%$12.67+414.9%N/A$123.12MN/A0.00N/AUpcoming EarningsEXOZeXoZymes1.114 of 5 stars$15.48+6.2%N/AN/A$122.17M$70K0.0029Positive NewsGap UpHigh Trading VolumeBMEABiomea Fusion3.5421 of 5 stars$2.10+2.4%$9.50+352.4%-78.8%$121.99MN/A-0.6950IKTInhibikase Therapeutics1.5824 of 5 stars$1.55flat$6.50+319.4%+32.5%$115.50MN/A-0.586 Related Companies and Tools Related Companies LFVN Alternatives KALA Alternatives PYXS Alternatives ONCY Alternatives ACOG Alternatives CGEN Alternatives HURA Alternatives EXOZ Alternatives BMEA Alternatives IKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
